FDA Approves a New Medication for Bronchiectasis

This post was co-authored by the Bronchiectasis and NTM Association and COPD Foundation Education teams.

What is Bronchiectasis?

Bronchiectasis is a chronic (long-lasting) lung disease that causes the bronchial airways – the tubes that carry air in and out of the lungs – to become widened, scarred, and inflamed.¹

Bronchiectasis can affect anyone. It is often seen with other lung conditions such as COPD, severe asthma, history of lung infections, and immunodeficiency.

Immunodeficiency is when the body is unable to fight germs and infections properly. In up to 50% of cases, bronchiectasis is caused from unknown reasons.¹ To learn more, download the “All About Bronchiectasis” booklet.

How the Disease Works

Damaged airways can lead to a buildup of mucus. This causes increased cough. Mucus in the lungs creates an environment that encourages the growth of germs. These germs can contribute to recurring infections, increased inflammation, and further damage. This process is known as the vicious vortex.¹

First FDA-approved medication for Bronchiectasis

A new medicine from Insmed Incorporated received FDA approval on August 12, 2025. Brinsupri™ (brensocatib) is a once-daily pill. It helps reduce exacerbations, or flare-ups, by targeting inflammation. This could result in improved outcomes for individuals with bronchiectasis.²

What You Need to Know:

1. Brinsupri is the first medication approved for bronchiectasis. It targets a root cause of inflammation. Until now, treatments were limited. People with bronchiectasis would use airway clearance to help prevent mucus buildup. They also would take medications to treat infections.
2. Brinsupri reduces flare-up frequency. This may slow the decline of lung function. This gives hope to many people.
3. Brinsupri has the potential to address a major unmet need. Bronchiectasis affects millions of people around the world.

Next Steps

Managing bronchiectasis involves several key factors: maintaining airway clearance, regular exercise, proper nutrition, taking medications, updating vaccines, avoidance of smoking, and getting quality sleep. Treatment for bronchiectasis is a unique journey for everyone. It is important to talk with your health care provider about whether new treatment options may be right for you.

Read more about Brinsupri.

References

1. Keir HR, Chalmers JD. Pathophysiology of Bronchiectasis. Semin Respir Crit Care Med. 2021;42(4):499-512. doi:10.1055/s-0041-1730891
2. Chalmers JD, Burgel PR, Daley CL, et al. Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. N Engl J Med. 2025;392(16):1569-1581. doi:10.1056/NEJMoa2411664